Related Experiment Videos

Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study

Randall E Harris1, Joanne Beebe-Donk, Galal A Alshafie

  • 1The Ohio State University College of Medicine & School of Public Health, Columbus, OH 43210, USA. Harris.44@osu.eduq

International Journal of Biological Sciences
|June 26, 2007
PubMed

Insights

Selective COX-2 inhibitors significantly reduce lung cancer risk by 60% with long-term use. Non-selective NSAIDs like ibuprofen and aspirin also showed risk reduction, unlike acetaminophen.

Area of Science:

  • Oncology
  • Pharmacology
  • Epidemiology

Background:

  • Lung cancer remains a leading cause of cancer-related mortality worldwide.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 (COX-2) inhibitors are widely used for pain and inflammation.
  • Previous research has suggested a potential link between NSAID use and reduced cancer risk, but the role of selective COX-2 inhibitors in lung cancer prevention is less understood.

Purpose of the Study:

  • To investigate the association between the use of selective COX-2 inhibitors and the risk of developing lung cancer.
  • To compare the effects of selective COX-2 inhibitors with non-selective NSAIDs (ibuprofen, aspirin) and acetaminophen on lung cancer risk.

Main Methods:

  • A case-control study was conducted with 492 newly diagnosed lung cancer cases and healthy controls.
  • Participants' information on the type, frequency, and duration of selective COX-2 inhibitor and NSAID use was collected.
  • Logistic regression analysis was used to estimate odds ratios (OR), adjusting for smoking, age, and other confounders.

Main Results:

  • Use of any selective COX-2 inhibitor for over one year was associated with a significant 60% reduction in lung cancer risk (OR=0.40).
  • Both ibuprofen (OR=0.40) and aspirin (OR=0.53) also demonstrated significant risk reductions.
  • Acetaminophen, with negligible COX-2 activity, showed no effect on lung cancer risk (OR=1.36).

Conclusions:

  • Selective COX-2 blocking agents, such as celecoxib and rofecoxib, show strong potential for the chemoprevention of human lung cancer.
  • Long-term use of selective COX-2 inhibitors may offer a protective effect against lung cancer development.
  • Further research is warranted to confirm these findings and explore the mechanisms underlying this protective effect.

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation